Autoantibody epitopes to the smaller isoform of glutamate decarboxylase do not differ in Swedish and Japanese type 1 diabetes patients and may be associated with high-risk human leucocyte antigen class II alleles

Clinical and Experimental Immunology

Volumn 150, Issue 3, 2007, Pages 416-421

  Maruyama, T ^a   Oak, S ^b   Hall, T R ^b   Banga, J P ^c   Ortqvist, E ^d   Ettinger, R A ^e   Endl, J ^f   Hampe, C S ^b  

^a Saitama Social Insurance Hospital   (Japan)

^b UNIVERSITY OF WASHINGTON   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d KAROLINSKA INSTITUTE   (Sweden)

^e BENAROYA RESEARCH INSTITUTE   (United States)

^f ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Autoimmune; GAD65; HLA; RBA; T1D

Indexed keywords

AUTOANTIBODY; EPITOPE; GLUTAMATE DECARBOXYLASE 65; HLA A2 ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; IMMUNOGLOBULIN F(AB) FRAGMENT; ISOENZYME;

ADOLESCENT; ADULT; AGED; ALLELE; ANTIGEN BINDING; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNITY; CHILD; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE ASSOCIATION; GENETIC ASSOCIATION; HAPLOTYPE; HIGH RISK PATIENT; HUMAN; INFANT; INSULIN DEPENDENT DIABETES MELLITUS; JAPANESE; MAJOR CLINICAL STUDY; MOLECULAR MODEL; NEWBORN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; AUTOANTIBODIES; AUTOIMMUNITY; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; EPITOPES; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; GLUTAMATE DECARBOXYLASE; HLA-DR ANTIGENS; HUMANS; INFANT; INFANT, NEWBORN; ISOENZYMES; MIDDLE AGED; TIME FACTORS;

EID: 36048975122     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2007.03527.x     Document Type: Article

References (30)

1. Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, LaPorte R, Tuomilehjto J. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (Diamond) Project Group. Diabetes Care 2000 23 : 1516 26.
2. Abiru N, Kawasaki E, Eguch K. Current knowledge of Japanese type 1 diabetic syndrome. Diabetes Metab Res Rev 2002 18 : 357 66.
3. Awata T, Kuzuya T, Matsuda A, Iwamoto Y, Kanazawa Y. Genetic analysis of HLA class II alleles and susceptibility Type 1 (insulin-dependent) diabetes mellitus in Japanese subject. Diabetologia 1992 35 : 419 24.
4. Falorni A, Grubin CE, Takei I et al. Radioimmunoassay detects the frequent occurrence of autoantibodies to the Mr 65,000 isoform of glutamic acid decarboxylase in Japanese insulin-dependent diabetes. Autoimmunity 1994 19 : 113 25.
5. Kasuga A, Falorni A, Maruyama T et al. HLA class II is associated with the frequency of glutamic acid decarboxylase Mr 65,000 autoantibodies in Japanese patients with insulin-dependent diabetes mellitus. Acta Diabetol 1996 33 : 108 13.
6. Undlien DE, Hamaguchi K, Kimura A et al. IDDM susceptibility associated with polymorphisms in the insulin gene region. A study of blacks, Caucasians and orientals. Diabetologia 1994 37 : 745 9.
7. Hashimoto M, Kinoshita T, Yamasaki M et al. Gene frequencies and haplotypic associations within the HLA region in 916 unrelated Japanese individuals. Tissue Antigens 1994 44 : 166 73.
8. Kawasaki E, Eguchi K. Is Type 1 diabetes in the Japanese population the same as among Caucasians? Ann NY Acad Sci 2004 1037 : 96 103.
9. Akamine H, Komiya I, Shimabukuro T et al. High prevalence of GAD65 (and IA-2) antibodies in Japanese IDDM patients by a new immunoprecipitation assay based on recombinant human GAD65. Diabet Med 1997 14 : 778 84.
10. Yano M, Moriuchi R, Kawasaki E et al. Autoantibodies against glutamic acid decarboxylase 65 in Japanese patients with insulin-dependent diabetes mellitus (IDDM). J Autoimmun 1995 8 : 83 96.
11. Padoa CJ, Banga JP, Madec AM et al. Recombinant Fabs of human monoclonal antibodies specific to the middle epitope of GAD65 inhibit type 1 diabetes-specific GAD65Abs. Diabetes 2003 52 : 2689 95.
12. Gilliam LK, Brooks-Worrell BM, Palmer JP, Greenbaum CJ, Pihoker C. Autoimmunity and clinical course in children with type 1, type 2, and type 1.5 diabetes. J Autoimmun 2005 25 : 244 50.
13. Schlosser M, Banga JP, Madec AM et al. Dynamic changes of GAD65 autoantibody epitope specificities in individuals at risk of developing type 1 diabetes. Diabetologia 2005 48 : 922 30.
14. Mire-Sluis A, Gaines Das R, Lernmark A. Standardization of antibody preparations for use in immunogenicity studies: a case study using the World Health Organization International Collaborative Study for Islet Cell Antibodies. Dev Biol (Basel) 2003 112 : 153 63.
15. Grubin CE, Daniels T, Toivola B et al. A novel radioligand binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM. Diabetologia 1994 37 : 344 50.
16. Carter P, Presta L, Gorman CM et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992 89 : 4285 9.
17. Madec AM, Rousset F, Ho S et al. Four IgG anti-islet human monoclonal antibodies isolated from a type 1 diabetes patient recognize distinct epitopes of glutamic acid decarboxylase 65 and are somatically mutated. J Immunol 1996 156 : 3541 9.
18. Jaume JC, Parry SL, Madec AM, Sonderstrup G, Baekkeskov S. Suppressive effect of glutamic acid decarboxylase 65-specific autoimmune B lymphocytes on processing of T cell determinants located within the antibody epitope. J Immunol 2002 169 : 665 72.
19. Schwartz HL, Chandonia JM, Kash SF et al. High-resolution autoreactive epitope mapping and structural modeling of the 65 kDa form of human glutamic acid decarboxylase. J Mol Biol 1999 287 : 983 99.
20. Tremble J, Morgenthaler NG, Vlug A et al. Human B cells secreting immunoglobulin G to glutamic acid decarboxylase-65 from a nondiabetic patient with multiple autoantibodies and Graves' disease: a comparison with those present in type 1 diabetes. J Clin Endocrinol Metab 1997 82 : 2664 70.
21. Banga JP, Moore JK, Duhindan N et al. Modulation of antigen presentation by autoreactive B cell clones specific for GAD65 from a type I diabetic patient. Clin Exp Immunol 2004 135 : 74 84.
22. Richter W, Endl J, Eiermann TH et al. Human monoclonal islet cell antibodies from a patient with insulin-dependent diabetes mellitus reveal glutamate decarboxylase as the target antigen. Proc Natl Acad Sci USA 1992 89 : 846 7.
23. Richter W, Shi Y, Baekkeskov S. Autoreactive epitopes defined by diabetes-associated human monoclonal antibodies are localized in the middle and C-terminal domains of the smaller form of glutamate decarboxylase. Proc Natl Acad Sci USA 1993 90 : 2832 6.
24. Richter W, Northemann W, Muller M, Bohm BO. Mapping of an autoreactive epitope within glutamate decarboxylase using a diabetes-associated human monoclonal autoantibody and an epitope cDNA library. Hybridoma 1996 15 : 103 8.
25. Grubin C, Daniels T, Karlsen AE, Boel E, Hagopian WA, Lernmark Å. The cDNA-directed, in vitro-synthesized nascent peptide of glutamic acid decarboxylase (GAD2) is the autoantigen in insulin-dependent diabetes. Clin Res 1992 40 : 299A.
26. Reveille JD. The genetic basis of autoantibody production. Autoimmun Rev 2006 5 : 389 98.
27. Vandewalle CL, Falorni A, Lernmark Å et al. Associations of GAD65- and IA-2-autoantibodies with genetic risk markers in new-onset IDDM patients and their siblings. Diabetes Care 1997 20 : 1547 52.
28. Kwok WW, Domeier ML, Raymond FC, Byers P, Nepom GT. Allele-specific motifs characterize HLA-DQ interactions with a diabetes-associated peptide derived from glutamic acid decarboxylase. J Immunol 1996 156 : 2171 7.
29. Harfouch-Hammoud E, Walk T, Otto H et al. Identification of peptides from autoantigens GAD65 and IA-2 that bind to HLA class II molecules predisposing to or protecting from type 1 diabetes. Diabetes 1999 48 : 1937 47.
30. Yu B, Gauthier L, Hausmann DH, Wucherpfennig KW. Binding of conserved islet peptides by human and murine MHC class II molecules associated with susceptibility to type I diabetes. Eur J Immunol 2000 30 : 2497 506.